Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ritter Pharmaceuticals Inc (RTTR): Knoll Capital Management Reports New Position

Page 1 of 7

Fred Knoll‘s Knoll Capital Management reported acquiring 526,903 common shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) via a 13G filing recently filed with the US Securities and Exchange Commission. The position represents a new addition to Knoll Capital Management’s portfolio, and the stake accounts for 6.14% of the company’s outstanding stock.

Ritter Pharmaceuticals, is a pharmaceutical company that works on developing therapeutics for treating gastrointestinal disorders. Since the beginning of the year, the company’s stock has gained 4.12%. In its last financial report, for the second quarter, Ritter Pharmaceuticals’ disclosed a net loss of $4.1 million or $0.48 per share, which compares to a loss of $2.3 million or $4.18 per share for the corresponding quarter a year earlier. The company did not generate any revenue during the period.

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, drugstore, service,


Among 749 hedge funds from our database, three were bullish on Ritter Pharmaceuticals (NASDAQ:RTTR) at the end of June, same as in the earlier quarter. Those smart money managers were Kevin Kotler‘s Broadfin Capital, which held $1.18 million worth of Ritter Pharmaceuticals’ shares, Julian and Felix Baker’s Baker Bros. Advisors, which owned a position worth $612,000, and Adam Usdan’s Trellus Management Company with a $28,000 worth a position.

Follow Ritter Pharmaceuticals Inc (NASDAQ:RTTR)
Trade (NASDAQ:RTTR) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Knoll Capital Management 0 526,903 0 526,903 526,903 6.14%
Fred Knoll 0 526,903 0 526,903 526,903 6.14%
Gakasa Holdings 0 526,903 0 526,903 526,903 6.14%

Fred Knoll
Fred Knoll
Knoll Capital Management

Page 1 of 7 – SEC Filing

Washington, D.C.  20549
(Rule 13d-102)
(Amendment No. __)
Ritter Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)


(CUSIP Number)

21, 2016

(Date of Event Which Requires Filing of the Statement)

Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)

*The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes)

Page 1 of 7

Follow Ritter Pharmaceuticals Inc (NASDAQ:RTTR)
Trade (NASDAQ:RTTR) Now!
Page 1 of 7

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!